Stay updated with breaking news from Recommended Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin),...
- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call
Share this article Share this article SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in non-small cell lung cancer (NSCLC) patients who acquired osimertinib-resistant EGFR triple mutations. BBT-176, a novel epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is designed to inhibit the signaling pathway of EGFR with...
/PRNewswire/ -- Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, today announced the U.S. Food and Drug Administration...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA January 27, 2021 GMT INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018, National OncoVenture (NOV), a government-funded virtual ...